



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: KINOSHITA=

In re Application of:) Art Unit: 1617
Shigeru KINOSHITA) Examiner: S.M.R. HUI
Serial No.: 09/623,138) Confirmation No. 9673
Filed: August 28, 2000) Washington D.C.
For: LANGERHANS CELL MIGRATION) October 29, 2002
INHIBITORS)

TECH CENTER 1600/2000

NOV 01 2002

RECEIVED

#9/E

11/5/02

11/5/02

11/5/02

AMENDMENT AFTER FINAL

Honorable Commissioner for Patents
Washington, D.C. 20231

In response to the Office Action of
July 30, 2002, please enter the following amendment:

IN THE CLAIMS

Please amend claim 11 as follows:

11. (Third Amendment) A method for
inhibiting ocular Langerhans cell migration in a mammal
comprising administering an effective amount of a
Langerhans cell migration inhibitor comprising a compound
selected from calcitriol; 1 α ,24-dihydroxy vitamin D₃; α -
calcidol; calcifedol; 1 α , 25,26-trihydroxy vitamin D₃;
1 β ,25-dihydroxy vitamin D₃; 24-homo-1 α ,25-dihydroxy
vitamin D₃; 26-homo-1 α ,25-dihydroxy vitamin D₃; 22-
oxacalcitol; and calcipotriol as an active ingredient to
the mammal, wherein the inhibition of said ocular
Langerhans cell migration results in the prevention or

do not enter
11/8/02

81

In re Application of: Shigeru KINOSHITA
 Serial No.: 09/623,138
 Filed: August 28, 2000
 For: LANGERHANS CELLS MIGRATION INHIBITORS



Art Unit: 1617
 Confirmation No.: 9673
 Examiner: S.M.R. HUI
 Washington, D.C.
 Atty.'s Docket: KINOSHITA=3
 Date: October 29, 2002

AE
 1617

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is an ☐ Amendment ☒ Amendment After Final
 in the above-identified application.

- ☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
☒ No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate		Additional Fee
Total	6	Minus	20		0		x 9	\$	x18
Indep.	1	Minus	3		0		x42	\$	x84
First Presentation of Multiple Dependent Claim							140	\$	+280
TOTAL ADDITIONAL CLAIMS FEE								\$	Total

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- ☐ First - \$ 55.00
☐ Second - \$200.00
☐ Third - \$460.00
☐ Fourth - \$720.00

Other Than Small Entity

Response Filed Within

- ☐ First - \$ 110.00
☐ Second - \$ 400.00
☐ Third - \$ 920.00
☐ Fourth - \$1440.00

☐ Less fees (\$) already paid for months extension of time on .

☐ Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

☐ A check in the amount of \$ is attached (check no.).

☐ Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ is attached.

☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:
 Anne M. Kornbau
 Registration No. 25,884

AMK:nmp

G:\BN\Y\YUAS\KINOSHITA3\Pro\cov3.wpd